Press Release

The United Kingdom Radiopharmaceutical Market to be dominated by Diagnostic Radiopharmaceuticals through 2028.

The increasing concern about health benefits is expected to drive the growth of the United Kingdom Radiopharmaceutical market in the forecast period, 2024-2028.

According to TechSci Research report, “United Kingdom Radiopharmaceutical Market - By Region, Competition Forecast and Opportunities, 2018-2028”, United Kingdom Radiopharmaceutical market is anticipated to grow at an impressive rate in the forecast period, 2024-2028This can be ascribed to the rising demand for targeted therapy with medical benefits such as targeting specific tumors, such as thyroid, lymphomas or bone metastases along with growing preference for diagnostic imaging among people are facing chronic diseases issues across the region. Additionally, rapid advances in science and technology, increasing healthcare expenditure, changes in food laws affecting label and product claims, and rising interest in attaining diseases free through treatment will escalate the growth of United Kingdom Radiopharmaceutical market in coming years. Besides, emergence of new product development PSMA PET Radiotracers, Theranostic Radiopharmaceutical, Alpha-emitting Radiopharmaceuticals, and Improved Imaging Agents will further be expected to support the United Kingdom Radiopharmaceutical market growth.

However, the regulation of radiopharmaceutical in United Kingdom can be complex, and there are hurdles Developing and bringing radiopharmaceuticals to market involves navigating complex regulatory processes. Obtaining regulatory approvals, such as those from the U.S. Food and Drug Administration (FDA), can be time-consuming and costly which can slow down the growth of United Kingdom Radiopharmaceutical market in the forecast period. Similarly, the limited availability of radioisotopes and the need for specialized infrastructure can pose constraints on the supply chain, which can lead to confusion among consumers which may hamper the United Kingdom Radiopharmaceutical market growth during the forecast period. Also, some radiopharmaceuticals rely on specific radioisotopes that may be prone to shortages. Factors such as limited production capacity, technical difficulties, and regulatory issues can contribute to these shortages. Supply disruptions of critical radioisotopes can impact patient care which can further restrict the growth of United Kingdom Radiopharmaceutical Market.



Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on United Kingdom Radiopharmaceutical Market.”



The United Kingdom Radiopharmaceutical market can be segmented by Type, Application, End User and by region. 

Based on Type, the United Kingdom Radiopharmaceutical market can be segmented into Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals. The Diagnostic Radiopharmaceuticals segment dominated the market in 2022 and is expected to continue maintaining its dominance throughout the forecast period. This can be ascribed to increasing Diagnostic radiopharmaceuticals for medical imaging to diagnose various conditions and diseases. They typically involve the use of gamma-emitting radioisotopes and imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Diagnostic radiopharmaceuticals help visualize physiological processes, assess organ function, detect tumors, evaluate cardiac conditions, and provide valuable diagnostic information. across the region. 

Based on Distribution Channel, the market can be segmented into Oncology, Cardiology, Neurology, Others {Respiratory, Musculoskeletal System Diseases, Thyroid, etc.}. The Oncology and Cardiology segment is expected to dominate during the forecast period on account of the rising awareness related to the Diagnostic radiopharmaceuticals, such as FDG-PET (Fluorodeoxyglucose positron emission tomography), are widely used for cancer staging, tumor detection, and assessing treatment response. Radiopharmaceuticals play a crucial role in cardiac imaging to evaluate myocardial perfusion, assess myocardial viability, and diagnose cardiac conditions. 


Major companies operating in United Kingdom Radiopharmaceutical market are:

  • GE Healthcare Ltd
  • Alliance Medical Ltd
  • Eckert & Ziegler Radio pharma GmbH
  • IBA Molecular Ltd
  • Mallinckrodt Pharmaceuticals Plc
  • Lantheus Medical Imaging Inc
  • Jubilant Radiopharma Inc
  • Sofie Biosciences Inc/United Kingdom

 

In 2014, Mallinckrodt acquire Questcor Pharmaceutical in cash and stock valued at approximately USD5.8 billion this is done because it will provide a strong and sustainable platform for future revenue and earnings growth and provide exceptional value for shareholders of both Mallinckrodt and Questcor.

In 2018, Alliance Medical Ltd acquires molecular imaging firms at undisclosed able amount the united company will offer imaging services, radiopharmacies, and cyclotrons, and is anticipated to improve access to imaging agents for clinical trials as well as provide integrated biomarkers.

In2021, the $3 billion ultrasound business at GE Healthcare expands beyond diagnostics to include therapeutic and surgical solutions. Significant synergies are anticipated to further boost BK Medical's renowned company as it adds competence in the rapidly expanding advanced surgical visualization market.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

“United Kingdom Radiopharmaceutical is expected to dominate the market during the forecast period on account due to the rising demand for targeted therapy with medical benefits along with growing preference for diagnostic imaging across the region. Furthermore, trend of personalized medication is growing, particularly among individuals with chronic medical conditions, where treatment is modernized which will further contributing to demand for United Kingdom Radiopharmaceutical market during the forecast period. Besides, increasing concern about healthy lifestyles and increasing expenditure on health and wellness is further expected to create lucrative opportunities for the market growth” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United Kingdom Radiopharmaceutical Market by Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Application (Oncology, Cardiology, Neurology, Others {Respiratory, Musculoskeletal System Diseases, Thyroid, etc.}), By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions, Others {Pharmaceutical Companies, Ambulatory Centers etc.}) and By Region and Competition”, has evaluated the future growth potential of United Kingdom Radiopharmaceutical Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United Kingdom Radiopharmaceutical Market.


Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com

Relevant News